Tempus AI, Inc. TEM
75.61 USD -2.19 (-2.81%)
At closeNov 5, 2026, 8:22 AM EST
73.24 -2.37 -3.13%
Pre-market · Nov 5, 8:22 AM ET
72.75 Day range 81.60
40.77 52-week range 89.09
- YTD
- +28.04%
- 1 year
- -8.08%
News
seekingalpha.com Tempus AI: An Inflection Point Has Arrived (Earnings Analysis) Tempus AI delivered robust Q3 results, with 23% YoY revenue growth and an inflection after four quarters of deceleration. Diagnostics volumes surged, notably MRD tests up 300% YoY, while Data &…
benzinga.com Nancy Pelosi Isn't Running for Re-Election in 2026 Midterms: Say Goodbye to Her Stock Picks in Two Months Nancy Pelosi is not seeking re-election Tuesday and will leave Congress in January 2027.
benzinga.com Jefferies Upgrades Tempus AI to Hold, Raises Price Target to $70 Jefferies analyst Tycho Peterson upgrades Tempus AI (NASDAQ:TEM) from Underperform to Hold and raises the price target from $35 to $70.
benzinga.com Freedom Capital Markets Maintains Hold on Tempus AI, Raises Price Target to $89 Freedom Capital Markets analyst Gene Mannheimer maintains Tempus AI (NASDAQ:TEM) with a Hold and raises the price target from $73 to $89.
marketbeat.com Tempus AI Surges on Earnings Beat, But Can the Rally Last? Tempus AI NASDAQ: TEM is among the more volatile AI-related stocks, trading in a wide range and testing upper limits several times since its IPO. Volatility stems from several factors, including the…
zacks.com TEM Q3 Earnings Call Highlights Growth and 2027 Pricing Upside Tempus AI raises its 2026 revenue outlook as oncology demand, expanding data partnerships and reimbursement-driven pricing gains fuel growth prospects for 2027.
benzinga.com Apple To $350? Here Are 10 Top Analyst Forecasts For Tuesday Analysts raised targets for TEM, TWLO, UPWK, MRSH and PLTR; cut MRVL and AAPL targets, with upgrades for TWLO and MRSH.
seekingalpha.com Baron SMID Cap ETF Q3 2026 Contributors And Detractors Baron SMID Cap ETF returned -2.87% (NAV) in the third quarter, outperforming its benchmark, the Russell 2500 Growth Index, which returned -10.35%. Top contributors were Rubrik, Inc., Tempus AI, Inc.,…
benzinga.com HC Wainwright & Co. Maintains Buy on Tempus AI, Raises Price Target to $85 HC Wainwright & Co. analyst Yi Chen maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price target from $68 to $85.
benzinga.com Tempus AI Analysts Boost Their Forecasts Following Strong Q3 Results Tempus AI Inc. (NASDAQ:TEM) on Monday posted upbeat results for the third quarter.
benzinga.com Tempus AI Analysts Boost Their Forecasts Following Strong Q3 Results Tempus AI beat Q3 estimates with $411.5M revenue and 7-cent adjusted EPS; analysts raised price targets, while shares slipped premarket.- benzinga.com Baird Maintains Outperform on Tempus AI, Raises Price Target to $92 Baird analyst Catherine Schulte maintains Tempus AI (NASDAQ:TEM) with a Outperform and raises the price target from $85 to $92.
benzinga.com Cantor Fitzgerald Maintains Overweight on Tempus AI, Raises Price Target to $92 Cantor Fitzgerald analyst Sarah James maintains Tempus AI (NASDAQ:TEM) with a Overweight and raises the price target from $80 to $92.
benzinga.com Jefferies Upgrades Tempus AI to Hold, Raises Price Target to $70 Jefferies analyst Tycho Peterson upgrades Tempus AI (NASDAQ:TEM) from Underperform to Hold and raises the price target from $35 to $70.
benzinga.com BTIG Maintains Buy on Tempus AI, Raises Price Target to $100 BTIG analyst Mark Massaro maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price target from $80 to $100.
zacks.com 3 Stocks to Watch Following Guidance Upgrades The Q3 earnings cycle continues to roll along, with several healthcare companies delivering positive results and raising their outlooks as a result.
247wallst.com Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge Tempus AI (NASDAQ:TEM | TEM Price Prediction) was trading higher this afternoon. It sat at $80.31, up 11.21% after the precision medicine company reported third-quarter results before the open.
seekingalpha.com Tempus AI, Inc. (TEM) Q3 2026 Earnings Call Transcript Tempus AI, Inc. (TEM) Q3 2026 Earnings Call Transcript
benzinga.com Needham Maintains Buy on Tempus AI, Raises Price Target to $89 Needham analyst Ryan MacDonald maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price target from $75 to $89.
benzinga.com Tempus AI Says It Is Uniquely Positioned Tempus AI Inc. (NASDAQ:TEM) shares were trading higher on Monday after the company reported third-quarter adjusted earnings of 7 cents per share, swinging from a loss of 8 cents, beating the…
benzinga.com Tempus AI Says It Is Uniquely Positioned Tempus AI stock rises after beating Q3 earnings estimates and securing $192.5 million in data deals with Bristol Myers Squibb and Pathos.
benzinga.com Dow Rises 1%, Oil Sinks 7% on Iran Peace Hopes: Stock Market Today Oil tumbles on renewed U.S.-Iran diplomacy, pulling Treasury yields lower and lifting the Dow, airlines and Amazon while energy stocks lag.
zacks.com Tempus (TEM) Reports Q3 Earnings: What Key Metrics Have to Say The headline numbers for Tempus (TEM) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
zacks.com Tempus AI (TEM) Beats Q3 Earnings and Revenue Estimates Tempus AI (TEM) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to a loss of $0.11 per share a year ago.
marketbeat.com What Tempus AI (TEM) Said on Its Q3 Earnings Call Tempus AI NASDAQ: TEM reported third-quarter 2026 revenue of $411.5 million, up 23% from a year earlier, as growth in oncology diagnostics and data-and-applications services continued to drive…
fool.com Tempus AI Revenue Up 23%; Gains Cut Net Loss: Rapid Earnings Reaction Data and Applications revenue grew 33% and earns gross margins above 71%, so its faster growth lifts company-wide margins. The adjusted EBITDA outlook held at about $65 million, implying a jump to…
barrons.com Tempus AI's Cancer Screen Business Drives Revenue Up 23%, While a Major Purchase Draws Closer Tempus AI reported better-than-expected third-quarter earnings.- benzinga.com Tempus AI Q3 Adj. EPS $0.07 Beats $(0.08) Estimate, Sales $411.537M Beat $409.350M Estimate Tempus AI (NASDAQ:TEM) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.08) by 187.5 percent. This is a 163.64 percent increase over losses of $(0.11)…
- benzinga.com Tempus AI Raises FY2026 Sales Guidance from $1.595B-$1.605B to $1.600B-$1.605B vs $1.592B Est Tempus AI (NASDAQ:TEM) raises FY2026 sales outlook from $1.595 billion-$1.605 billion to $1.600 billion-$1.605 billion vs $1.592 billion estimate.
businesswire.com Tempus Reports Third Quarter 2026 Results CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended…
defenseworld.net Head-To-Head Contrast: Tempus AI (NASDAQ:TEM) versus P3 Health Partners (NASDAQ:PIII) P3 Health Partners (NASDAQ: PIII - Get Free Report) and Tempus AI (NASDAQ: TEM - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two…
benzinga.com Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott…
benzinga.com Tempus AI Earnings Ahead: Is TEM Set Up To Pop or Drop? Tempus AI, a company that Cathie Wood has invested in, will publish its financial results this week as its volatility continues.
defenseworld.net Tempus AI (NASDAQ:TEM) Stock: Insider Eric Lefkofsky Sells 250,000 Shares Tempus AI, Inc. (NASDAQ: TEM - Get Free Report) CEO Eric Lefkofsky sold 250,000 shares of the stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $70.36, for…
zacks.com TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now? Tempus AI or Doximity: Which medical information systems stock offers better value? Compare growth prospects, AI expansion, earnings estimates and valuation.- benzinga.com Tempus AI's XR Assay Receives EU Certification As A Class C In Vitro Diagnostic Device The certification covers Tempus’ quality management system for "next-generation sequencing devices for cancer genomic profiling to support clinical management."xR detects gene rearrangements and…
- benzinga.com HC Wainwright & Co. Maintains Buy on Tempus AI, Raises Price Target to $68 HC Wainwright & Co. analyst Yi Chen maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price target from $66 to $68.
benzinga.com Tempus AI Enters Multiyear Agreement With Bristol Myers Squibb For BMY To License Multimodal Oncology Data Through 2031 To Support Biological And Clinical Insight Identification, Novel Drug Target Discovery And Therapeutic Development Across Its Oncology Portfolio Additionally, BMS will gain access to Tempus’ Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world’s largest, real-world multimodal datasets. Connected…- benzinga.com Tempus AI To Present Results From Study Evaluating AI-Enabled Pre-Screening Panel For Patients With Advanced Non-Small Cell Lung Cancer, At ESMO Congress 2026 Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology imagesTempus AI, Inc. (NASDAQ:TEM)…
- benzinga.com Canaccord Genuity Maintains Buy on Tempus AI, Raises Price Target to $95 Canaccord Genuity analyst Kyle Mikson maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price target from $80 to $95.
benzinga.com Palantir CTO Says Some AI Researchers Are So Sure It Will Cure Cancer They’ve Started 'Smoking' — Warns Both AI Extremes Reflect ‘Social Delusion’ Palantir CTO Shyam Sankar calls AI doomsday predictions theological, while warning that extreme optimism amounts to ‘mass psychosis,'
benzinga.com Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.
benzinga.com S&P 500, Nasdaq Hit Records, Power Stocks Rally on Google's Nuclear Deal: Stock Market Today S&P 500 and Nasdaq 100 hit records as the 10-year yield retreats from a 24-year high; Constellation Energy jumps on a Google nuclear deal.
benzinga.com Cathie Wood Claps Back After Being Confronted as ARKK Fell Nearly 15% While QQQ Soared 112% in Five Years — Calls It an ‘Incorrect Comparison’ Cathie Wood defends ARKK's 15% drop vs QQQ's 112% 5-year gain, calling it an 'incorrect comparison' and blaming 'endpoint sensitivity.'
benzinga.com Stock Market Today: S&P 500 Slips as Micron Fails to Impress, 10-Year Yields Ease to 5.25% Micron slides despite a record quarter as the 10-year yield nears 5.3% and oil tops $92, while Accenture, Coherent and Vicor surge on earnings and AI optics.- benzinga.com Guggenheim Maintains Buy on Tempus AI, Raises Price Target to $92 Guggenheim analyst Subbu Nambi maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price target from $65 to $92.
- benzinga.com Tempus AI Receives 510(k) Clearance From FDA For Tempus ECG-MR, AI Product That Analyzes Standard 12-Lead Resting Ecgs To Detect Signs Associated With Undiagnosed Mitral Regurgitation ECG-MR becomes the fourth FDA-cleared Tempus ECG-AI product, spanning arrhythmia, heart function, pulmonary vascular and valvular diseaseTempus AI, Inc. (NASDAQ:TEM) today announced it has received…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Tempus AI Extends Recursion Data Deal Through 2029, Replacing Potential $84M Fees With $42M In Committed Payments, In Addition To Licensing Recursion’s RNA Foundation Model "TxFM" Under A Separate License Agreement Tempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). Additionally, the two companies have entered into a new…
benzinga.com This Digital Realty Trust Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Wall Street initiated coverage on XRN, TEM, NNE, SECZ with ratings from Neutral to Buy and price targets of $21.20-$75.